Bayer sells a product against testosterone deficiency | News

Bayer is parting ways with its Nebido drug for men and selling it to the drug manufacturer Grünenthal for up to € 500 million. The product contract for the treatment of testosterone deficiency in men is expected to be concluded by the end of 2022.

The revenues will support investment in future innovation and develop transformative treatment options for patients, Bayer said. The sale is part of Bayer’s ongoing transformation of pharmaceutical operations to focus on key areas of future medical innovation.

Grünenthal acquires worldwide product rights for the agent. This also includes contract operations in the US where Irish pharmaceutical company Endo Pharmaceuticals sells the active ingredient as a licensee. Grnenthal expects the testosterone drug to contribute to around € 100 million in operating profit (EBITDA) in the coming year. In the past fiscal year, Nebido, with market presence in more than 80 countries, contributed EUR 117 million of Bayer’s pharmaceutical sales of EUR 18.3 billion.

Register now and buy Bayer shares

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

According to Grünenthal, Nebido is the leading brand in the treatment of testosterone deficiency in men. The product is still patented in the EU until March 2024, in the US until May 2027. In recent years, Grünenthal has strengthened itself with numerous acquisitions and has invested over two billion euros in them.

Bayer stock is improving significantly

Bayer stock is the best stock of the year with a nearly 20 percent plus. However, the situation has worsened since June. Support at just below 55 euro and the uptrend line are currently being tested. The MACD (Momentum) has already dropped to a new low this year, but has been able to stabilize for a few days.

Bayer’s success can be seen through purchase of shares participate. Brave investors can get leverage with Buy CFDs get involved.

It’s that simple to buy stocks on eToro.

The eToro platform offers traders from all over the world the unique opportunity to add shares to their portfolio. As of early 2018, every BUY non-leveraged order causes eToro to buy the underlying asset; it will then be held on behalf of the client. This also applies to cases where you invest in CopyPortfolio or copy an investor: if the copied investor buys shares, you automatically own a portion of his share portfolio.

Trade stocks with eToro, here are the advantages:

  • trust Your shares will be held in your name in an EU regulated company.
  • insurance Your deposit and related assets are insured under CySEC’s Terms of Use.
  • dividends If the company pays dividends, investors will be allocated an appropriate dividend.
  • No care fees Buying stocks on eToro means you no Pay storage and ordering fees as well as commissions. There is a bid-ask spread when buying and selling stocks.
  • Easy-to-use Your warehouse is always available online and via the app.
  • diversification Create a portfolio of stocks, cryptocurrencies, commodities and more.

Register now and buy stocks

About eToro:

For over a decade, eToro has been at the forefront of the global fintech revolution. It is the world’s leading social trading network, with millions of registered users and a host of innovative trading and investing tools. Since the beginning of 2018, eToro allows you to buy and sell stocks.

More: https://www.etoro.com/ CFDs are complex instruments and come with a high risk of losing money rapidly through leverage. 67% of retail investor accounts lose money when trading CFDs from this provider. You should consider whether you understand how CFDs work and whether you can afford the high risk of losing your money.

advertisement

Leave a Comment